A Phase 1 interventional study of CP-690,550 and CP-690,550 in Juvenile Idiopathic Arthritis, sponsored by Pfizer. Completed at 10 sites in 4 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-07-04.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Juvenile by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Juvenile · Pfizer.
Among the 10 studies in Arthritis, Juvenile by Pfizer, this one is one of 2 that started in 2013, is the only one in phase 1, and was the 7th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →1 of the 10 studies in Arthritis, Juvenile by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 2–17
By country, each count listing its studies:
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 5 · Phase 4 1
First in 2002; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 127 across the 7 interventional studies, 100 across the 3 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Arthritis, Juvenile by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase 1 study to describe pharmacokinetics of CP-690,550 in pediatric patients 2 to less than 18 years of age with Juvenile Idiopathic Rheumatoid Arthritis (JIA).
This is an open-label, non-randomized, multi-center, oral CP-690,550, multiple-dose (twice daily for 5 days [except Day 5 when only morning dose will be given]) study in pediatric subjects with JIA aged from 2 to less than 18 years. Baseline visit will occur within 1 month of the completion of the Screening Visit. The study will consist of three cohorts based on the age of the subjects, Cohort 3: 2 to less than 6 years, Cohort 2: 6 to less than 12 years and Cohort 1: 12 to less than 18 years. In each cohort, at least 8 pediatric subjects with JIA will participate in the study ensuring a total number of at least 24 pediatric evaluable subjects completing the PK period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Infections:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ages 12 to less than 18
Drug: CP-690,550
Ages 6 to less than 12
Drug: CP-690,550
Ages 2 to less than 6
Drug: CP-690,550
CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
Also known as: Tofacitinib
CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
Also known as: Tofacitinib
CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing \<30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
Also known as: Tofacitinib
Apparent Oral Clearance (CL/F)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is also influenced by the fraction of the dose absorbed. Clearance was estimated by non compartmental analysis (NCA) of PK data. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing the given oral dose by AUCtau. AUCtau is the area under the plasma concentration time-curve from time zero to end of dosing interval.
Time frame: Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose
Number of Participants With Treatment-Emergent Adverse Events (AEs) All Causalities
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs included both serious and non-serious AEs.
Time frame: Baseline up to 28 days after the last dose of study drug (Day 5)
Number of Participants With Laboratory Test Abnormalities
Participants with laboratory test abnormalities of potential clinical concern without regard to baseline abnormality were reported. Criteria: Hematology(hemoglobin,hematocrit,red blood cell\[RBC\] count:\<0.8\*lower limit of normal \[LLN\], platelets:\<0.5\*LLN/greater than \[\>\]1.75\*upper limit of normal\[ULN\], white blood cell \[WBC\] count:\<0.6\*LLN\>\</0\>1.5\*ULN, lymphocytes, total neutrophils:\<0.8\*LLN or \>1.2\*ULN, basophils, eosinophil, monocytes:\>1.2\*ULN); Liver Function (total bilirubin: \>1.5\*ULN, aspartate aminotransferase,alanine aminotransferase, alkaline phosphatase:\>3.0\*ULN, total protein, albumin:\<0.8\*LLN or \>1.2\*ULN);Renal Function (blood urea nitrogen, creatinine:\>1.3\*ULN, uric acid:\>1.2\*ULN); Electrolytes (sodium:\<0.95\*LLN or \>1.05\*ULN,potassium,chloride,calcium,bicarbonate:\<0.9\*LLN or \>1.1\*ULN);Clinical chemistry (glucose \<0.6\*LLN or \>1.5\*ULN, creatine kinase:\>3.0\*ULN); Urinalysis (Urine WBC and RBC: greater than or equal to \[\>=\] 6/High Power Field \[HPF\]).
Time frame: Baseline up to Day 5
Number of Participants With Clinically Significant Vital Signs Abnormalities
Criteria for vital signs of potentially clinical concern included supine/sitting pulse rate of \<40 beats per minute (bpm) or \>120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, systolic blood pressure of \>=30 millimeters of mercury (mmHg) change from baseline and systolic blood pressure \<90 mmHg, diastolic blood pressure \>=20 mmHg change from baseline and diastolic blood pressure \<50 mm Hg.
Time frame: Baseline up to Day 5
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
Time frame: Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose
Maximum Observed Plasma Concentration (Cmax)
Time frame: Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose
Apparent Volume of Distribution (Vz/F)
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose
Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose
Taste Assessment
Participants were evaluated for taste assessment using a 5 categories questionnaire. Participants were asked to answer one of the following to describe the taste of oral solution of tofacitinib: Dislike very much, dislike a little, not sure, like a little, or like very much. The taste assessment was only performed for participants who received the oral solution. Number of participants within each category are reported.
Time frame: Day 1, Day 5
| Milestone | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years |
|---|---|---|---|
| Started | 8 | 9 | 9 |
| Completed | 8 | 9 | 9 |
| Not completed | 0 | 0 | 0 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is also influenced by the fraction of the dose absorbed. Clearance was estimated by non compartmental analysis (NCA) of PK data. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing the given oral dose by AUCtau. AUCtau is the area under the plasma concentration time-curve from time zero to end of dosing interval.
| liter per hour | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years |
|---|---|---|---|
| Apparent Oral Clearance (CL/F) | 28.09 ± 22 | 25.48 ± 40 | 20.53 ± 33 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs included both serious and non-serious AEs.
| participants | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years |
|---|---|---|---|
| AE | 1 | 1 | 2 |
| SAE | 0 | 0 | 0 |
Participants with laboratory test abnormalities of potential clinical concern without regard to baseline abnormality were reported. Criteria: Hematology(hemoglobin,hematocrit,red blood cell\[RBC\] count:\<0.8\*lower limit of normal \[LLN\], platelets:\<0.5\*LLN/greater than \[\>\]1.75\*upper limit of normal\[ULN\], white blood cell \[WBC\] count:\<0.6\*LLN\>\</0\>1.5\*ULN, lymphocytes, total neutrophils:\<0.8\*LLN or \>1.2\*ULN, basophils, eosinophil, monocytes:\>1.2\*ULN); Liver Function (total bilirubin: \>1.5\*ULN, aspartate aminotransferase,alanine aminotransferase, alkaline phosphatase:\>3.0\*ULN, total protein, albumin:\<0.8\*LLN or \>1.2\*ULN);Renal Function (blood urea nitrogen, creatinine:\>1.3\*ULN, uric acid:\>1.2\*ULN); Electrolytes (sodium:\<0.95\*LLN or \>1.05\*ULN,potassium,chloride,calcium,bicarbonate:\<0.9\*LLN or \>1.1\*ULN);Clinical chemistry (glucose \<0.6\*LLN or \>1.5\*ULN, creatine kinase:\>3.0\*ULN); Urinalysis (Urine WBC and RBC: greater than or equal to \[\>=\] 6/High Power Field \[HPF\]).
| participants | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years |
|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities | 3 | 1 | 5 |
Criteria for vital signs of potentially clinical concern included supine/sitting pulse rate of \<40 beats per minute (bpm) or \>120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, systolic blood pressure of \>=30 millimeters of mercury (mmHg) change from baseline and systolic blood pressure \<90 mmHg, diastolic blood pressure \>=20 mmHg change from baseline and diastolic blood pressure \<50 mm Hg.
| participants | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years |
|---|---|---|---|
| Number of Participants With Clinically Significant Vital Signs Abnormalities | 0 | 0 | 0 |
| nanogram*hour per milliliter (ng*hr/mL) | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years |
|---|---|---|---|
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) | 156.6 ± 25 | 118.8 ± 27 | 142.5 ± 32 |
| nanogram per milliliter (ng/mL) | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 46.97 ± 40 | 41.67 ± 29 | 66.15 ± 28 |
| hours | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years |
|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 0.750 ± 25 | 1.00 ± 27 | 0.500 ± 32 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
| liter | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years |
|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) | 104.9 ± 35 | 71.0 ± 40 | 51.44 ± 34 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hours | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years |
|---|---|---|---|
| Plasma Decay Half-Life (t1/2) | 2.616 ± 0.454 | 1.949 ± 0.294 | 1.771 ± 0.406 |
Participants were evaluated for taste assessment using a 5 categories questionnaire. Participants were asked to answer one of the following to describe the taste of oral solution of tofacitinib: Dislike very much, dislike a little, not sure, like a little, or like very much. The taste assessment was only performed for participants who received the oral solution. Number of participants within each category are reported.
| participants | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years |
|---|---|---|---|
| Day 1: Dislike very much | 0 ± 0.45350 | 1 ± 0.29396 | 1 ± 0.40634 |
| Day 1: Dislike a little | 0 | 0 | 2 |
| Day 1: Not sure | 1 | 1 | 1 |
| Day 1: Like a little | 1 | 3 | 1 |
| Day 1: Like very much | 0 | 2 | 4 |
| Day 5: Dislike very much | 0 | 1 | 0 |
| Day 5: Dislike a little | 1 | 0 | 3 |
| Day 5: Not sure | 1 | 2 | 1 |
| Day 5: Like a little | 0 | 2 | 2 |
| Day 5: Like very much | 0 | 2 | 3 |
Collected over Baseline up to 28 days after the last dose of study drug (Day 5). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort I: 12 Years to <18 Years | — | 0/8 (0%) | 1/8 (12.5%) |
| Cohort II: 6 Years to <12 Years | — | 0/9 (0%) | 1/9 (11.1%) |
| Cohort III: 2 Years to <6 Years | — | 0/9 (0%) | 2/9 (22.2%) |
| Event | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years |
|---|---|---|---|
| FatigueGeneral disorders | 1/8 | 0/9 | 0/9 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 1/9 | 0/9 |
| Viral infectionInfections and infestations | 0/8 | 0/9 | 1/9 |
| BlisterSkin and subcutaneous tissue disorders | 0/8 | 0/9 | 1/9 |
The safety analysis population included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years | Total |
|---|---|---|---|---|
| Mean | 14.1 ± 2.0 | 9.4 ± 1.8 | 4.0 ± 1.0 | 9.0 ± 4.5 |
| Sex: Female, Male(Participants) | Cohort I: 12 Years to <18 Years | Cohort II: 6 Years to <12 Years | Cohort III: 2 Years to <6 Years | Total |
|---|---|---|---|---|
| Female | 5 | 5 | 7 | 17 |
| Male | 3 | 4 | 2 | 9 |
The record gives a start of Mar 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib